Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform
Rhea-AI Summary
Medicus Pharma (NASDAQ:MDCX) announced a non-binding LOI with Reliant AI on December 22, 2025 to develop an AI-driven clinical data analytics platform aimed at improving site selection, patient stratification, and enrollment forecasting for Teverelix and other programs.
Medicus completed the acquisition of Antev in August 2025 to add Teverelix and reported clinical milestones for SkinJect: 90 patients enrolled in SKNJCT-003, topline results planned Q1 2026, FDA Type C feedback supporting a 505(b)(2) pathway, and U.K. regulatory approvals for Phase 2 expansion.
Positive
- Acquisition of Antev completed in Aug 2025
- Teverelix targets a ~$6 billion combined market opportunity
- 90 patients enrolled in SKNJCT-003 (Phase 2)
- U.K. MHRA/HRA/WREC approvals received for Phase 2 expansion
- FDA Type C feedback supports 505(b)(2) pathway for SkinJect
Negative
- LOI with Reliant AI is non-binding; no guarantee of definitive deal
- Initial Reliant engagement financial cap is only $200,000
- Interim SKNJCT-003 results described as preliminary and unconfirmed
Key Figures
Market Reality Check
Peers on Argus 1 Down
Key peers showed mixed moves, from -2.84% (SCLX) to +6.8% (IXHL), while only one momentum-scanner peer (RMTI at -4.62%) appeared, suggesting MDCX’s modest +1.81% move was more company-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 15 | Clinical enrollment update | Positive | -3.2% | Completion of 90-patient Phase 2 SKNJCT-003 enrollment across 9 U.S. sites. |
| Dec 05 | Warrant inducement financing | Positive | +3.5% | Warrant inducement to raise about $5.1M gross via accelerated exercises. |
| Dec 01 | Management & program update | Positive | -10.2% | CFO appointment plus SkinJect and Teverelix development and regulatory updates. |
| Nov 24 | Pipeline progress overview | Positive | -7.0% | Antev acquisition and data on next‑generation prostate and BCC therapies. |
| Nov 17 | Regulatory voucher filing | Positive | +4.5% | Filing of FDA Commissioner’s CNPV application for SKNJCT-003 BCC program. |
Recent positive clinical and corporate updates often saw mixed or negative price reactions, with 3 divergences versus 2 alignments.
Over the last months, Medicus reported several pipeline and corporate milestones, including a CNPV application for SKNJCT-003 on Nov 17, 2025, broader prostate and skin cancer updates on Nov 24, 2025, a CFO appointment with program progress on Dec 1, 2025, a $5.1M warrant inducement on Dec 5, 2025, and completion of 90-patient Phase 2 enrollment on Dec 15, 2025. Price reactions to these largely positive announcements were often negative, so today’s constructive AI collaboration news comes against a backdrop of mixed historical trading responses.
Market Pulse Summary
This announcement outlines a data-driven strategy to support Medicus’ pipeline, particularly Teverelix and the SkinJect BCC programs, via an AI-powered clinical analytics platform with up to $200,000 in milestone-based services. It builds on recent milestones such as completion of 90-patient Phase 2 enrollment and regulatory clearances across the U.S., UK, and UAE. Key factors to monitor include execution of definitive Reliant AI agreements, Phase 2 SkinJect readouts in 2026, and progression of Teverelix toward late-stage studies.
Key Terms
pharmacodynamic medical
505(b)(2) regulatory pathway regulatory
investigational medicinal product dossier regulatory
good clinical practice regulatory
expanded access ind program regulatory
AI-generated analysis. Not financial advice.
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute urinary retention (AURr) and high CV risk prostate cancer collectively representing ~
PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / December 22, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it has entered into non-binding letter of intent (LOI) with Reliant AI Inc. ("Reliant"), a decision-intelligence company for the life sciences, specializing in generative AI, to collaborate on the development of an artificial-intelligence-powered data analytics platform designed to support clinical trial execution through data-driven insights.
Reliant AI Inc. is a privately held decision-intelligence company powering the next generation of life sciences research with generative AI. Founded by former DeepMind and Google Brain researchers Karl Moritz Hermann and Marc Bellemare, and life sciences expert Richard Schlegel, Reliant AI combines cutting-edge machine learning with deep biomedical expertise The company's platform automates data-intensive workflows-from systematic literature reviews to commercial success prediction-enabling biopharma teams to make faster, evidence-based decisions.
The proposed platform is intended to enhance data-driven decision-making across Medicus' clinical pipeline by integrating Reliant's proprietary AI technology with Medicus' clinical, operational, and proprietary datasets. The platform is expected to support more efficient trial execution, including dynamic clinical-site selection, patient stratification, and enrollment forecasting. The initial phase of the collaboration will focus on dynamic site selection, supported by targeted patient-stratification analyses, for an upcoming Teverelix clinical study planned to commence in 2026.
"This proposed collaboration reflects an important strategic step of selectively deploying advanced analytics and AI tools to improve the efficiency, quality, and predictability of clinical development," stated Dr. Raza Bokhari, Medicus Exec. Chairman & CEO "by integrating AI-enabled modeling with our clinical and pharmacodynamic data, we aim to support more precise trial execution while maintaining capital discipline We see this as the foundation for a broader, data-driven clinical execution capability. Starting with Teverelix, our goal is to apply these insights to improve trial efficiency, inform patient selection, and support smarter decision-making as our programs move toward late-stage development."
Planned Clinical Development Applications
Subject to execution of definitive agreements, the data analytics platform is expected to be initially deployed to support a Medicus-sponsored study planned for Q2-Q4 2026, with potential expansion to a larger, late-stage clinical study planned for 2028 in collaboration with a development or commercial partner.
Initial areas of focus under the LOI include:
Dynamic site selection and re-selection during active patient recruitment
Enrollment simulations and forecasting across geographies
Comparative site-selection strategies to support study planning and partnering discussions
Early pharmacodynamic (PD)-informed patient stratification to optimize inclusion criteria and analytical focus
The platform is expected to leverage public, commercial, and Medicus proprietary datasets to analyze disease burden, geographic distribution, and patient-subgroup characteristics, with the ability to scale into broader feasibility and stratification modules over time.
Proposed Commercial Structure
Subject to the execution of definitive agreements, Medicus and Reliant intend to structure the initial collaboration as a one-year, milestone-based services engagement with an aggregate financial commitment not to exceed $200,000, tied to defined delivery milestones over a 12-month period. The Company shall also make available all relevant clinical and operational resources to support this engagement.
Non-Binding Nature of the LOI
The letter of intent is non-binding, and does not create a partnership, joint venture, or agency relationship between the parties. Ownership, intellectual property rights, governance, and final commercial terms will be addressed, if at all, in definitive agreements. There can be no assurance that a definitive agreement will be executed or that the proposed collaboration will proceed as contemplated.
Skinject Clinical Development Program SKNJCT-003 & SKNJCT-004 Progress:
The Company is currently conducting a Phase 2 clinical study for SKNJCT-003 in nine (9) clinical sites across the United States. SKNJCT-003, which commenced randomizing patients in August 2024, is a double blinded, placebo controlled triple arm proof of concept Phase 2 clinical study, designed to non-invasively treat basal cell carcinoma (BCC) of the skin using novel, patent protected, dissolvable doxorubicin-containing microneedle arrays (D-MNA). In December 2025, the Company announced that it has successfully completed enrolment of ninety (90) patients in the United States for phase 2 clinical study (SKNJCT-003). The Company expects to release topline results for SKNJCT-003 in the first quarter of 2026 and secure an end of phase 2 (EOP2) meeting with the FDA in the first half of 2026.
In March 2025, the Company announced a positively trending interim analysis for SKNJCT-003 demonstrating more than
In September 2025, the Company received positive feedback from the Food and Drug Administration (FDA) regarding its Type C meeting supporting the development of SkinJect, indicating that the Company may follow the FDA's 505(b)(2) regulatory pathway to non-invasively treat BCC of the skin using dissolvable D-MNA.
In October 2025, the Company treated its first patient in the clinical study (SKNJCT-004) currently underway in the United Arab Emirates (UAE). The study is expected to randomize thirty-six (36) patients in six (6) sites in the UAE with Cleveland Clinic Abu Dhabi (CCAD) as the principal investigator. Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.
In November 2025, the Company received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating D-MNA to non-invasively treat BCC of the skin. The approvals were issued by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA) and the Wales Research Ethics Committee (WREC). The MHRA approval followed a comprehensive scientific review of the Investigational Medicinal Product Dossier (IMPD) and protocol. The WREC issued a favorable ethical opinion, and the HRA granted study wide governance approval, confirming compliance with U.K. Good Clinical Practice and National Health Service capacity and capability standards.
Skinject Platform Expansion:
In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the "MoU") with Helix Nanotechnologies, Inc. ("HelixNano"), a Boston-based biotech company focused on developing a proprietary advanced mRNA platform, to explore co-development of thermostable infectious disease vaccines.
Pipeline Expansion-Acquisition of Antev
In August 2025, the Company completed the acquisition of Antev Limited ("Antev"), a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.
Antev's flagship drug candidate is Teverelix trifluoroacetate, a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.
Patient Access & Advocacy-Gorlin Syndrome Alliance Collaboration
In October 2025, the Company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SkinJect™, the Company's investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.
Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the FDA to allow patients with multiple, recurrent, or inoperable BCCs of the skin to access SkinJect™ under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SkinJect™ in this rare disease population.
For further information contact:
Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com
Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicuspharma.com
About Reliant AI Inc.
Reliant AI Inc. is a privately held decision-intelligence company powering the next generation of life sciences research with generative AI. The company's platform automates data-intensive workflows-from systematic literature reviews to commercial success prediction-enabling biopharma teams to make faster, evidence-based decisions.
Founded by former DeepMind and Google Brain researchers Karl Moritz Hermann and Marc Bellemare, and life sciences expert Richard Schlegel, Reliant AI combines cutting-edge machine learning with deep biomedical expertise. The company has offices in Montreal, Canada, and Berlin, Germany, and is backed by Tola Capital and Inovio Capital. For more information, visit www.reliant.ai.
About Medicus Pharma Ltd.
Medicus Pharma Ltd. (Nasdaq:MDCX) is a precision guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.
SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The Company completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.
In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the "MoU") with Helix Nanotechnologies, Inc. ("HelixNano"), a Boston-based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.
In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.
Antev's flagship drug candidate is Teverelix trifluoroacetate, a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.
In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than
In January 2023, the FDA, reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev's proposed Phase 3 trial design for Teverelix. This milestone supports the Company's clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.
In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.
In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients
In October 2025, the Company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SkinJect™, the Company's investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.
Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the Food and Drug Administration (FDA) to allow patients with multiple, recurrent, or inoperable basal cell carcinomas (BCCs) to access SkinJect™ under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SkinJect™ in this rare disease population.
In November 2025, the Company received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. The approvals were issued by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA) and the Wales Research Ethics Committee (WREC). The MHRA approval followed a comprehensive scientific review of the Investigational Medicinal Product Dossier (IMPD) and protocol. The WREC issued a favorable ethical opinion, and the HRA granted study wide governance approval, confirming compliance with U.K. Good Clinical Practice and National Health Service capacity and capability standards.
In December 2025, the Company announced that it has successfully completed enrolment of ninety (90) patients in the United States for phase 2 clinical study (SKNJCT-003) evaluating D-MNA to non-invasively treat BCC of the skin. The Company expects to release topline results for SKNJCT-003 in the first quarter of 2026 and secure an end of phase 2 (EOP2) meeting with the FDA in the first half of 2026.
Cautionary Notice on Forward-Looking Statements
Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company's leadership and prospects, the collaboration with GSA including the potential benefits thereof for GSA, those suffering with Gorlin Syndrome and Medicus (including as it relates to the development of SkinJect™), ability to be approved for the Expanded Access IND Program to enable those suffering with Gorlin Syndrome to access SkinJect™ under physician-supervised treatment protocols, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr and high CV risk prostate cancer, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano's proprietary mRNA vaccine platform with Medicus's proprietary microneedle array (MNA) delivery platform, the Company's aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, including with respect to the Company's submission for approval in the FDA Commissioner's National Priority Voucher program, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the Company's expectation to release topline results for SKNJCT-003 in the first quarter of 2026 and to secure an EOP2 meeting with the FDA in the first half of 2026, entry into definitive documents with Reliant and the expected terms thereof, engaging in proposed Medicus-sponsored studies currently contemplated in the Reliant non-binding letter of intent and the expected benefits thereof, the expansion of SKNJCT-003 into the United Kingdom and the potential benefits therefrom, the advancement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "could," "designed," "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target", "potential" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's annual report on form 10-K for the year ended December 31, 2024 (the "Annual Report"), and in the Company's other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
SOURCE: Medicus Pharma Ltd
View the original press release on ACCESS Newswire
FAQ
What did Medicus Pharma (MDCX) announce on December 22, 2025?
How much is Medicus committing to the Reliant AI services engagement for MDCX?
What is the status of SkinJect Phase 2 (SKNJCT-003) for MDCX and when are topline results due?
What regulatory progress has Medicus reported for SkinJect and Teverelix (MDCX)?
What clinical applications will the Reliant AI platform target for MDCX's Teverelix program?
Does the Reliant AI LOI create a binding partnership for Medicus (MDCX)?
